Salarius Pharmaceuticals Inc (SLRX) Actualités

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting

Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in...

Form 8-K - Current report

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Company implementing a series of cost-savings measures designed to extend Salarius’ expected cash runway into...

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein...

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse...

Form SC 13D - General statement of acquisition of beneficial ownership